Department of Clinical and Experimental Medicine, Department of Hematology, County Council of Östergötland, Linköping University, SE-58185 Linköping, Sweden.
BMC Cancer. 2013 Jun 4;13:274. doi: 10.1186/1471-2407-13-274.
NOTCH1 PEST domain mutations in chronic lymphocytic leukemia have recently been shown to be of prognostic relevance. Both NOTCH1 and NOTCH2 are constitutively activated in B-cell CLL but not expressed in normal B cells and may be involved in survival and resistance to apoptosis in CLL. We screened for mutations in different parts of both NOTCH1 and NOTCH2 genes and related the changes to survival and other known risk factors.
In a cohort of 209 CLL patients, we used single strand conformation analysis to determine which of the samples carrying the NOTCH mutations and direct dideoxy sequencing was used to determine the exact nucleotide changes. Kaplan-Meier curves and log rank test were used to determine overall survival for NOTCH1 mutated cases and Cox regression analysis was used to calculate hazardous ratios.
In the present study, we found NOTCH1 PEST domain mutations in 6.7% of the cases. A shorter overall survival was found in patients with NOTCH1 mutations compared to wildtype (p = 0.049). Further, we also examined the extracellular and the heterodimerisation domains of the NOTCH1 gene and the PEST domain and heterodimerisation domain of the NOTCH2 gene, but no mutations were found in these regions. NOTCH1 mutations were most commonly observed in patients with unmutated IGHV gene (10/14), and associated with a more aggressive disease course. In addition, NOTCH1 mutations were almost mutually exclusive with TP53 mutations. In the combined group of NOTCH1 (6.7%) or TP53 (6.2%) mutations, a significant difference in overall survival compared to the wildtype NOTCH1 and TP53 was found (p = 0.002).
Both NOTCH1 and TP53 mutations seem to be independent predictive markers for worse outcome in CLL-patients and this study emphasizes the contention that NOTCH1 mutations is a novel risk marker.
最近的研究表明,慢性淋巴细胞白血病(CLL)中的 NOTCH1 PEST 结构域突变具有预后相关性。NOTCH1 和 NOTCH2 在 B 细胞 CLL 中均持续激活,但在正常 B 细胞中不表达,可能与 CLL 中的存活和抗凋亡有关。我们筛选了 NOTCH1 和 NOTCH2 基因的不同部分的突变,并将这些变化与存活和其他已知的危险因素相关联。
在 209 例 CLL 患者的队列中,我们使用单链构象分析来确定哪些样本携带 NOTCH 突变,并使用直接双脱氧测序来确定确切的核苷酸变化。Kaplan-Meier 曲线和对数秩检验用于确定 NOTCH1 突变病例的总生存率,Cox 回归分析用于计算危险比。
在本研究中,我们发现 6.7%的病例存在 NOTCH1 PEST 结构域突变。与野生型相比,NOTCH1 突变患者的总生存率较低(p=0.049)。此外,我们还检查了 NOTCH1 基因的细胞外区和异二聚化区以及 NOTCH2 基因的 PEST 结构域和异二聚化区,但在这些区域未发现突变。NOTCH1 突变最常见于未突变的 IGHV 基因患者(14 例中的 10 例),并与更具侵袭性的疾病过程相关。此外,NOTCH1 突变几乎与 TP53 突变互斥。在 NOTCH1(6.7%)或 TP53(6.2%)突变的联合组中,与野生型 NOTCH1 和 TP53 相比,总生存率有显著差异(p=0.002)。
NOTCH1 和 TP53 突变似乎都是 CLL 患者预后不良的独立预测标志物,本研究强调了 NOTCH1 突变是一种新的风险标志物。